|
Sync-Rx - a 42% Elron Company
(indirectly through RDC)
Improved trans-catheter cardiovascular interventions
Sync-Rx seeks to develop and introduce major improvements in the simplicity, efficacy and safety of trans-catheter cardiovascular interventions. The company is developing add-on products to existing imaging and tools that are commonly used at cardiovascular catheterization labs. The Sync-Rx products fit seamlessly into current work flow and require no modifications whatsoever to existing equipment. The company is targeting two specific trans-catheter procedures, coronary angioplasty and heart valve replacement.
|